Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies

• Rocio Vicario ,

  Contributed equally to this work with: Rocio Vicario, Vicente Peg

  Affiliations Preclinical Oncology Program, Vall d’Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, 08035, Barcelona, Spain, Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Campus de la UAB, 08193, Bellaterra, Spain

  ⨯
• Vicente Peg ,

  Contributed equally to this work with: Rocio Vicario, Vicente Peg

  Affiliation Pathology Department, Vall d’Hebron University Hospital, 08035, Barcelona, Spain

  ⨯
• Beatriz Morancho,

  Affiliation Preclinical Oncology Program, Vall d’Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, 08035, Barcelona, Spain

  ⨯
• Mariano Zacarias-Fluck,

  Affiliation Preclinical Oncology Program, Vall d’Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, 08035, Barcelona, Spain

  ⨯
• Junjie Zhang,

  Affiliation Preclinical Oncology Program, Vall d’Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, 08035, Barcelona, Spain

  ⨯
• Águeda Martínez-Barriocanal,

  Affiliation Preclinical Oncology Program, Vall d’Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, 08035, Barcelona, Spain

  ⨯
• Alexandra Navarro Jiménez,

  Affiliation Pathology Department, Vall d’Hebron University Hospital, 08035, Barcelona, Spain

  ⨯
• Claudia Aura,

  Affiliation Molecular Oncology Program, Vall d’Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, 08035, Barcelona, Spain

  ⨯
• Octavio Burgues,

  Affiliation Pathology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, 46010, Valencia, Spain

  ⨯
• Ana Lluch,

  Affiliation Oncology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, 46010, Valencia, Spain

  ⨯
• Javier Cortés,

  Affiliation Clinical Oncology Program, Vall d’Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, 08035, Barcelona, Spain

  ⨯
• Paolo Nuciforo,

  Affiliation Molecular Oncology Program, Vall d’Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, 08035, Barcelona, Spain

  ⨯
• Isabel T. Rubio,

  Affiliation Clinical Oncology Program, Vall d’Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, 08035, Barcelona, Spain

  ⨯
• Elisabetta Marangoni,

  Affiliation Translational Research Department, Institut Curie, 75005, Paris, France

  ⨯
• James Deeds,

  Affiliation Novartis Oncology Translational Research, Cambridge, MA, 02139, United States of America

  ⨯
• Markus Boehm,

  Affiliation Novartis Pharma AG, Postfach, CH-4002, Basel, Switzerland

  ⨯
• Robert Schlegel,

  Affiliation Novartis Oncology Translational Research, Cambridge, MA, 02139, United States of America

  ⨯
• Josep Tabernero,

  Affiliation Clinical Oncology Program, Vall d’Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, 08035, Barcelona, Spain

  ⨯
• Rebecca Mosher ,

  * E-mail: jarribas@vhio.net (JA); rebecca.mosher@novartis.com (RM)

  Affiliation Novartis Oncology Translational Research, Cambridge, MA, 02139, United States of America

  ⨯
•  [ ... ],
• Joaquín Arribas

  * E-mail: jarribas@vhio.net (JA); rebecca.mosher@novartis.com (RM)

  Affiliations Preclinical Oncology Program, Vall d’Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, 08035, Barcelona, Spain, Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Campus de la UAB, 08193, Bellaterra, Spain, Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010, Barcelona, Spain

  ⨯
• [ view all ]
• [ view less ]